Cancer Network Staff

Cervical cancer survivors saw improvements in self-reported quality-of-life outcomes with a psychosocial telephone counseling intervention, according to a new study.

In two phase II trials, the protein synthesis inhibitor omacetaxine offered long-term efficacy in some patients with chronic-phase and accelerated-phase CML.

Researchers have shown that axitinib could be repurposed as a treatment for CML patients resistant to standard TKIs through a certain molecular mechanism.

Women in routine gynecologic care expressed willingness to extend screening intervals and use cytology alone or Pap-HPV cotesting if recommended by a physician.

An inhibitor of osteoclast formation can stop the proliferation of dormant tumor cells that in some breast cancer survivors turn into bone metastases.

Conservative management of cervical intraepithelial neoplasia (CIN) grade 2 is an appropriate treatment option for women aged 25 years and younger.

Active surveillance is effective and yields good outcomes in patients with clinical stage I testicular cancer who underwent orchiectomy.

A test for dangerous strains of high-risk HPV using messenger RNA was shown to be reliable and effective for cervical cancer risk stratification.

A study of nivolumab compared with docetaxel in patients with squamous cell NSCLC was stopped early after an analysis showed superiority of the study drug.